Skip to main content
profile image
Selected Works of Philip Mease, MD
Article
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
The Lancet (2018)
  • Philip Mease, University of Washington
  • Laura C Coates, University of Oxford
  • Philip S Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK
  • Mykola Stanislavchuk, National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • Anna Rychlewska-Hanczewska, Ai Centrum Medyczne, Poznan, Poland
  • Anna Dudek, Centrum Medyczne AMED, Warszawa, Poland
  • Walid Abi-Saab, Galápagos NV
  • Chantal Tasset, Galápagos NV
  • Luc Meuleners, Galápagos NV
  • Pille Harrison, Galápagos NV
  • Robin Besuyen, Galapagos BV, Leiden, Netherlands
  • Annegret Van der Aa, Galápagos NV
  • Neelufar Mozaffarian, Gilead Sciences, Foster City, CA, USA
  • Joy M Greer, Gilead Sciences, Foster City, CA, USA
  • Rebecca Kunder, Gilead Sciences, Foster City, CA, USA
  • Filip Van den Bosch, Ghent University
  • Filip Van den Bosch, Ghent University Hospital
  • Dafna D Gladman, Toronto Western Hospital
Link
Disciplines
Publication Date
December 1, 2018
DOI
10.1016/S0140-6736(18)32483-8
Citation Information
Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, et al.. "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial" The Lancet Vol. 392 Iss. 10162 (2018) p. 2367 - 2377
Available at: http://works.bepress.com/philip-mease/323/